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ABSTRACT
Clostridia are gram-positive spore-forming organisms responsible for a variety of 
diseases in both humans and animals. Three species of Clostridia- Clostridium difficile, 
Clostridium sordellii and Clostridium novyi- produce a unique class of toxins termed 
large clostridial toxins (LCTs). These toxins inactivate members of the Ras superfamily 
of mammalian GTPases by glycosylation. LCTs are important in a variety of diseases, 
for example, Toxin A (TcdA) and toxin B (TcdB) are the major virulence factors in C. 
difficile associated diarrhea and pseudomembranous colitis. Whereas Clostridium 
sordellii lethal toxin (TcsL) and Clostridium novyi alpha toxin (Tenet) have been 
implicated in gas gangrene infections. In addition to their roles in disease, TcdB and 
TcsL have been extensively used to decipher the effects of inactivating Ras proteins in 
mammalian cells. In order to better understand the role of these toxins in inactivating 
Ras proteins, we have undertaken the molecular characterization of intoxication by two 
LCTs, TcsL and TcdB. A chimeric fusion protein consisting of the TcdB enzymatic 
domain fused to the binding and translocation regions of anthrax lethal toxin (LFnTcdB*' 
^^ )^ was able to confer cytopathic effects on tissue culture cells and in a mouse, when 
delivered with the protective antigen (PA) component of anthrax toxin. Fusions 
containing mutants in the enzymatic domain of TcdB (LFnTcdB*'^ ®**, LFnTcdB 
LFnTcdB*'*^®, LFnTcdB^ '^^^^ LFnTcdB®’'^^^ LFnTcdB^^^^ LFnTcdB^^^^^, 
LFnTcdB*'^ *®^ '^ ) were inactive for glucosylation and CPE on cells, with the exception of 
LFnTcdB^^^^  ^ and LFnTcdB*'*^ **. The fusion proteins attenuated in enzymatic activity 
acted as inhibitors of TcdB both in vivo and in vitro. LFnTcdB 1-500 was also able to
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inhibit the activity of TcsL and slowed cell rounding in transformed mammalian cells 
expressing the enzymatic domain of TcdB indicating the competition was occurring 
inside the cytosol. A combination of the lysosomotropic agent Bafilomycin A1 and the 
LFnTcdB 1-500 inhibitor was used to determine the time required for cytosolic entry and 
irreversible cytopathic effects after treatment with TcdB. Furthermore, the time required 
for TcsL cytosolic entry was found to be considerably slower than that of TcdB 
accounting for the lower CPE of TcsL compared to TcdB.
IX
Literature Review
A variety of bacteria secrete extracellular toxins capable of entering into and modifying 
mammalian cells. The most frequent means of accomplishing cellular entry appears to be 
via receptor mediated endocytosis. After being internalized, the toxin must traffic to the 
cytosol where it carries out its enzymatic action. To this effect, the toxin or at least an 
active fragment of the toxin, must translocate from the lumen of the endocytic vesicle 
into the cytosol. Endosomal acidification may be required for insertion and translocation 
across the vesicular membrane. In addition, many toxins including anthrax toxin, ricin, 
diphtheria toxin, and Pseudomonas exotoxin require proteolytic cleavage and/or 
reduction for activation [1]. Unfortunately, the mechanisms of entry and intoxication for 
LCTs have not been well studied.
The mechanism of action of LCTs is of particular interest since Clostridium sordellii and 
Clostridium novyi toxins have been implicated in gas gangrene infections and 
Clostridium difficile TcdA and TcdB are major virulence factors in C. difficile associated 
disease (CDAD) [2]. An estimated 300,000-3,000,000 people in the United States 
contract CD AD each year [2]. While CD AD is usually mild, the disease can be quite 
severe and 15-30 percent of those affected relapse within 2 months after treatment [3]. 
CDAD can be fatal in the elderly and immune suppressed, and C. difficile infections have 
become an increasing problem for individuals suffering from AIDS [4].
TcdA acts as an enterotoxin and is considered to be the major cause of fluid accumulation 
and diarrhea caused by C. difficile', while, TcdB is an effective cytotoxin, possesses 1000 
times greater enzymatic activity than TcdA, and is responsible for systemic intoxication 
[5]. The role of C sordellii and C. novyi LCTs in wound infections is not as well 
understood. Due to the large size of LCTs and the lack of genetic techniques for 
manipulating clostridia, these toxins have not been extensively characterized. Gaining a 
basic understanding of the structure/function of these toxins may lead to improved 
therapies for clostridial infections involving LCTs.
LCTs
The LCTs are a unique class of virulence factors generated by at least three pathogenic 
clostridial species. C. difficile produces TcdA and TcdB, C. novyi makes Tcna, and C. 
sordellii produces TcsL and hemorrhagic toxin (TcsH). These toxins are exceptionally 
large (ranging from 260-308 kDa) and function as glycosyltransferases to inactivate Ras 
proteins [5-7]. TcdA, TcdB, TcsL, and TcsH all use UDP-glucose as a cosubstrate, 
whereas alpha-toxin uses UDP-N-acetyl glucosamine to modify target substrates.
Since LCTs disrupt GTPase coordinated activities, they have proven to be valuable 
molecular tools for dissecting the roles of Ras proteins in cellular physiology. C. difficile 
TcdB is a LCT that modifies Rho proteins by glucosylation at T35 of Rac and Cdc42 
(T37 for RhoA) resulting in the inactivation of downstream signaling pathways. TcdB, 
disrupts tight junctions, increases epithelial permeability, and promotes actin
condensation and cell death [8-10]. TcsL, on the other hand, modifies Ras, Rac, and Rap 
[11]. More recently TcsL has also been shown to target Ral and Cdc42 and to a much 
lesser extent RhoA [12]. Ras proteins control growth and differentiation, and 
glucosylation of Ras proteins at T35 by TcsL also results in inactivation and cell death.
T he R as  superfam ilv of proteins
The first of the Ras proteins were discovered in the 1970s using animal tumor virus 
models; however, they were of little interest until 1982 when the gene encoding H-ras 
became the first identified human oncogene [13]. Since then, a widespread interest in 
Ras proteins has lead to the identification of over 80 Ras related proteins, all of which are 
categorized under the Ras superfamily. The Ras superfamily of proteins share at least 
30% homology and are further divided, based on sequence and functional similarities, 
into 5 families: Ras, Rho, Rah, Arf and Ran. These proteins act as molecular switches by 
cycling between an inactive GDP bound and an active GTP bound form. Ras proteins 
receive intracellular and extracellular (mediated through integral membrane proteins) 
signals and transmit these signals by activating specific kinase cascades. These kinase 
cascades result in the coordinated control of a variety of cellular functions including 
endocytosis, secretion, transcription, protein modification, cell migration, actin 
cytoskeleton dynamics and cell cycle progression, which collectively regulate cell growth 
(for reviews see[14,15]).
R as proteins in hum an d ise a se
Since the discovery of Ras in tumor transformation there has been an intense interest in 
the function of these small GTP binding proteins. Mutations in Ras have now been 
identified in over 30% of lung adenocarcinoma and myeloid leukemia. While Ras 
mutations occur as often as 50% and 90% in colon adenocarcinoma and pancreas 
adenocarcinoma, respectively [16]. Although constitutively active Rho GTPases do not 
lead to cell transformation, these proteins play a role in metastasis, invasion and 
angiogenesis [17, 18]. Several Rho activating proteins are known oncogenes and 
apparently transform cells in a Ras independent manner. In addition to their role in 
cancer, the Ras superfamily of proteins have been linked to several physiological 
functions including embryo development, bone formation, neuronal growth, 
neurotransmitter exocytosis, muscle contraction, endothelial cell migration associated 
with wound repair, and migration of immune system cells in inflammatory response [19- 
21]. Not surprisingly, these proteins are now being linked to genetic disorders 
(Faciogenital dysplasia), immune system disorders (Human phagocyte 
immunodeficiency), and vesicular disorders (hypertension, cerebral vasospasm, 
myocardial hypertrophy) [22-24]. Ras proteins control a plethora of cellular and 
physiological functions and although it is beyond the scope of this dissertation research, 
are potential drug targets for a variety of diseases.
T he Rho family of R as-rela ted  G T P ases
The Rho family of Ras related GTPases is composed of 10 different members (some with 
multiple isoforms) as diagrammed in Figure 1 [14]. RhoA, Racl, and Cdc42 are the best 
understood of the Rho family GTPases, and are targets for C difficile TcdB in vitro [25]. 
While isoforms of RhoA, Racl, and Cdc42 have not been determined to be substrates for 
glucosylation, the similarity of the Rho proteins suggest they are all targets for 
modification by TcdB.
Rho proteins share many common structural features and possess intrinsic GTPase 
activity. Modifications in regions conferring the GTPase activity produce constitutively 
active GTP bound forms, while modifications that prevent the exchange of GDP for GTP 
result in inactivation of downstream signaling (Figure 2). The crystal structures of Rho, 
in both the GDP and GTP bound forms, reveal that the exchange of GDP for GTP causes 
structural changes in loop 1 (26aa-45aa) and loop 2 (59aa-74aa) exposing recognition 
sites for effector proteins [26, 27]. An insert region (123aa-135aa) is the major 
distinguishing characteristic of Rho family GTPases that differentiates them firom other 
members of the Ras family, and in the case of Rac, this region is also involved in effector 
binding [28]. The Rho family of GTPases is highly conserved in amino acid composition 
as well as in function, and the major effects of sequence variations seem to be on their 
ability to interact with specific regulatory and effector proteins.
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Figure 1. Dendrogram of Rho GTPases. This dendrogram shows the 
relative homology, at the amino acid level, of the Rho family members. 
Differential splicing results in multiple isoforms for Rnd, Rho, and Rac 
proteins. Additionally, G25K is an isoform of Cdc42. Rho, Rac and Cdc42 
share 51% homology overall, while Rac and Cdc42 are 75% homologous.
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Figure 2. Sequence Alignments for RhoA, Racl, and Cdc42. The effector-binding 
region of RhoA, Racl, and Cdc42, indicated in the figure, interacts with downstream 
effector proteins and is also the site of modification by TcdB and C3 exoenzyme from 
Clostridium botulinum. Sequences indicative of GTPase activity are underlined and 
mutations in at least two of these regions result in constitutively active GTP bound forms 
of the proteins. Cytotoxic Necrotizing Factor (CNF) and Dermonecrotic Toxin (DNT) 
fi’om E. coli also produce constitutively active forms of the GTPases by deaminating 
Q61. The site for cleavage and isoprenylation (required for recruitment to the membrane 
where they carry out their activity) is indicated in this figure as well.
The activation state of Rho proteins depends on the interaction of Rho with one of three 
regulatory proteins. Two regulatory factors are responsible for maintaining Rho in an 
inactive GDP bound form: GTPase activating protein (GAP) and Guanine dissociation 
Inhibitor (GDI). These regulatory proteins stimulate intrinsic GTP hydrolysis and 
stabilize the GDP bound cytosolic form of Rho proteins, respectively. Guanine exchange 
factors (GEFs) are the central regulatory factor in Rho activation, they respond to a 
variety of cellular signals and activate Rho by catalyzing the exchange of GDP for GTP.
The interaction between Rho and its regulatory proteins is complex. For instance, RhoA 
alone associates with at least 7 different GAPs and GEFs (Figure 3). In addition, 5 of the 
RhoA GEFs and 5 of the GAPs are shared with at least one other Rho family member. 
Recent experiments suggest that in addition to responding to activation signals, GEFs 
may also regulate the affinity of Rho proteins for specific effector proteins, at least for 
Rac and Cdc42 [29]. GEFs, GAPs, and GDIs act on Rho proteins controlling the 
activation state and effector interaction of Rho family proteins.
Effectors of Rho proteins
Each GTPase binds to specific effectors and activates phosphorylation cascades. The 
GTP bound form of RhoA interacts with several effectors, which are divided into three 
groups according to homology in the RhoA binding region. The regions are called Rho 
effector motif class 1 (REM), ROK kinectin homology region class 2 (RKH), and a third 
class of effectors that do not share homology with either the REM or the RKH domains.
Effector 
Signaling
GAPs
GAP-N/190RhoG^ Conplex
Graf-2
Myr-5
pl22
pSORhoG^
pl90B
pl90RhoG^
GTP
RhoA
SmgGds
Figure 3. RhoA Interaction With Regulatory Proteins. Multiple GAPs interact with 
RhoA and stimulate GTP hydrolysis. GDI maintains the inactive (GDP bound ) form of 
RhoA in the cytosol and GEFs (of which there are also multiple forms) stimulate the 
exchange of GDP for GTP allowing the protein to cycle from the cytosol to the membrane 
and activate downstream effector proteins.
A complete list of RhoA effectors can be seen in Figure 4. Rac and Cdc42 are more 
closely related to each other than to RhoA, and share many of the same effector proteins 
(Figure 5). Several of the Rac and Cdc42 targets share a common Rac/Cdc42 binding 
motif (CRIB). RhoA shares 5 effector proteins with Rac and has no common effectors 
with Cdc42 (for a review see [30]). The effectors of the other Rho family members have 
not been identified.
Rho Pro teins and  Transcription
Several of the signaling pathways for Rac and Cdc42 effector kinases have been 
deciphered. For example, INK a common Rac and Cdc42 target protein activates a 
signaling cascade that results in the activation of c-Jun and c-Fos transcription factors, 
which activate transcription at the API promoter element. Additionally, p38K may also 
be activated downstream of PAK, activating the ATF transcription factor and initiating 
transcription at the cyclic AMP response element (CRE) [31, 32]. Rho has been recently 
shown to induce expression from the serum response element (SRE) through 
transcriptional activation of serum response factor (SRF) (see Figure 6) [33]. Generally 
these cascades are very specific, however some cross talk occurs between pathways. 
Adding to the complexity, in some cases, it may be necessary for these transcription 
factors to form complexes with other protein factors before initiating transcription at 
certain promoters. Bacterial toxins that activate or inactivate Ras related GTPases are 
ideally suited to study further these signal transduction pathways.
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Figure 4. RhoA effector proteins. RhoA interacts with a variety of downstream effectors, which include 
kinases, structural proteins, and heteromeric G proteins. These effectors can be divided into three groups based 
on different RhoA binding regions: REM, RKH, and a third with no homology to the first two. Either directly 
or indirectly, these effectors regulate actin polymerization and organization.
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Figure 5. Downstream effector proteins for Rac and Cdc42. Rac activates effector proteins involved 
in the regulation of actin polymerization and cytoskeleton organization, as well as regulation of NADPH 
oxidase complex. Cdc42 also regulates actin assembly and polymerization through interaction with 
different effector proteins. Both Rac and Cdc42 activate Jun-N-terminal kinase and stimulate 
mitogenesis. The effectors that interact with the common Rac, Cdc42 CRIB binding motif are shown in 
red.
T he R as superfam ilv: T argets of bacterial toxins
In addition to being potential drug targets, Ras related GTPases are the most common 
intracellular targets of bacterial virulence factors. Protein toxins produced by gram- 
positive and gram-negative bacteria are responsible for both inactivating and activating 
Ras and/or Rho GTPases. For example, Eschericia coli cytotoxic necrotizing factor 
(CNF) and Bordetella bronchioseptica dermonecrotic toxin (DNT) deaminate Glu63 
blocking GTPase activity and activating Rho by locking it in the GTP bound form [34]. 
Inactivating toxins include the 5 LCTs. Exoenzyme S produced by Pseudomonas 
aeruginosa activates Rho family members but inactivates Rab and Ras family GTPases 
[34, 35]. Clearly, the study of Ras superfamily proteins is far reaching since it impacts 
our understanding of numerous human pathogens.
LCTs- Structural F ea tu res
Like many intracellular toxins, LCTs can be roughly divided into enzymatic, 
translocation and receptor binding domains. The amino-terminal end of LCTs contain 
the enzymatic domain, followed by a hydrophobic region believed to be involved in 
translocation and then finally the receptor-binding domain located within the carboxy- 
terminal third of the toxin [34]. Through deletion studies, the enzymatic domain has been 
narrowed to approximately 550 amino acids [12, 36, 37]. Further deletions at the 3’ end 
of this fragment have been shown to attenuate enzymatic activity and deletion of the first 
244 residues renders TcdB enzymatically inactive [38]. Within the enzymatic region, 
tryptophan 102 has been shown to be involved in UDP-glucose binding for TcdB, TcsL,
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Figure 6. Signaling cascades activated by Rho GTPases. Rac and Cdc42 
activate Protein Activating Kinase (PAK) leading to the activation of ATF, c-jun 
and c-fos transcription factors. Rho acts through one of several effector proteins 
to activate serum response factor (SRF) leading to activation of transcription at 
the serum response element.
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and a-toxin [39]. Additionally, a DXD motif at position 286-288 which is common to a 
group of glucosyltransferases has been identified as important for glucosylhydrolase 
activity of LCTs [39]. The substrate recognition region has been narrowed to the 
carboxy-terminal region of the enzymatic domain, but the exact residues involved in 
substrate recognition have not been identified. Exchange of residues 364-468 of TcsL for 
those residues of TcdB change substrate targeting to favor TcdB target GTPases, while 
exchange of the same residues of TcdB for those of TcsL does not favor targeting of Ras, 
Rap, and Ral [12]. Smaller substitutions have not been tested for substrate recognition. 
Taken together these results indicate that the residues responsible for binding Rho, Rac, 
and Cdc42 are located somewhere between residues 364-468, while the Ras, Rap and Ral 
recognition residues lie somewhere between residues 364-516, see Figure 7 [12]. 
Truncated forms of TcdB have been expressed in E. coli and the enzymatic domain has 
been partially characterized using this approach, however, characterization of deletion 
mutants was precluded by lack of receptor binding/translocation functions and it was 
necessary for these mutants to be microinjected [36, 38]. Furthermore, the requirement 
for microinjection prevented analysis of the enzymatic domain in animal models. To 
address these problems we have utilized a translocation active, yet non-toxic, form of 
anthrax toxin to deliver the enzymatic domain of TcdB (TcdB^’^ ^^ ) and mutant 
derivatives to the cytosol of mammalian cells.
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Rho, Rac, and Cdc42
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Rho, Rac, Cdc42, Ras, Rap, Ral
Rac, Cdc42 
Rho, Rac, Cdc42
Figure 7. Chimeric fusions of the enzymatic domains of TcsL and TcdB. The substrate recognition 
region of TcdB was found to reside somewhere within residues 364-516. Recognition of TcsL 
substrates (Ras, Rap, and Ral) required both this region, and the region between 468-516.
Anthrax Toxin Delivery System
Anthrax toxin is a tripartite bacterial toxin in which protective antigen (PA) mediates the 
cytosolic delivery of lethal factor (LF) or edema factor (EF). Previous work by Arora et 
al. [40] and Milne et al. [41] showed that a translocated form of LF (LFn: 254 residues) 
could be used in conjxmction with PA as a delivery system to carry heterologous 
polypeptides into the cytosol of mammalian cells. In subsequent work [42] the PA-LFn 
system has been used to deliver the enzymatic domains of intracellular toxins, as well as, 
a novel approach for priming cytotoxic T-lymphocyte [43,44].
LFnTcdB Fusion Proteins
In this work, the enzymatic domain of TcdB fused to LFn (LFnTcdB^’^ ^^ ) was delivered 
to cells and was found to confer similar effects as native TcdB in tissue culture cells and 
in a mouse model system [45]. Additionally, fusions of three carboxy- terminal deletions 
(LFnTcdBLFnTcdB^^^”, LFnTcdB^’*’®), two amino terminal deletions (LFnTcdB^^" 
336, LFnTcdB^’-336) and three site directed mutants (LFn^^^ LFn^^3w Lp^wiozA  ^were 
generated and tested for the ability to hydrolyze UDP-glucose and transfer the glucose 
moiety to Rho protein substrates. During the analysis of these fusion proteins, we 
discovered a set of mutant proteins unable to modify substrate were capable of blocking 
TcdB cytopathic effects. Herein I describe the generation and analysis of these mutants 
and detail the role of these proteins as inhibitors of LCTs. In addition to providing 
insight into the functional domain of TcdB, these mutants also suggest a new type of
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therapeutic approach that could ameliorate the symptoms caused by intracellular 
virulence factors.
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MATERIALS AND METHODS
T issue  Culture. Mice, bacterial s tra ins and  chem ical reag en ts
Chinese Hamster Ovary-Kl (ATCC) cells were maintained in Ham’s F-12 medium 
(Gibco BRL) supplemented with 10% fetal bovine serum. Human cervical 
adenocarcinoma cells ATCC CCL-2 (HeLa) were grown in supplemented RPMI 1640 
(RP-10) [46] with 10% fetal bovine serum. Human Fetal Lung Fibroblasts (GM05387; 
NIGMS Human Genetic Mutant Cell Repository, Camden, NJ) between passage 8 and 
21, were grown in complete medium (MEM with high glucose Gibco BRL) 200U/ml 
penicillin and 200pg/ml streptomycin). Tissue culture cells were incubated at 37°C in a 
humid atmosphere with 6% CO2. All mice were female BALB/c (Jackson Laboratories), 
between 8 and 12 weeks of age. Clostridium difficile strain VPI 10463 and Clostridium 
sordellii strain 9714 were obtained from ATCC and used as a source of culture 
supernatant, genomic DNA, TcdB and TcsL. All reagents were of molecular biology 
grade and were purchased from Sigma Chemical Company unless otherwise noted.
Bafilomvcin A1 inhibition experim ents
A time course of TcdB cytosolic entry was performed in a 96 well plate. CHO cells (5 x 
10“* cells/well) were plated in a volume of 100 pi RP10 and allowed to adhere overnight. 
The following day, cells were treated with or 200 frnol TcdB. Bafilomycin A1 (5 x 10'^
2 0
M) was added to TcdB treated wells at 10-minute intervals up to 80 min. CPE were 
determined by cell rounding and were recorded at 8 and 16 hours after initial toxin 
treatment. A similar experiment was performed using TcsL (1 pmol). For the TcsL 
experiment, Bafilomycin A1 was added at two additional time points (100 and 120 min) 
and CPE were recorded after 16 hours.
Cloning TcdBi-Mm T cd B u m . TcdBi.^?n. TcdBi.i7n. TcdBam-mmm. and  TcdSsy-sfifi
Clostridium difficile genomic DNA was isolated using an Easy-DNA™ Kit (Invitrogen) 
according to the manufacturer’s instructions. A 1665 nucleotide fragment was amplified 
from the 5’ end of tcdB. IJh was genetically ftised with tcdB\.\(^s by cloning the fragment 
into the BamH 1 site of pABII, a derivative of pETlSb, which contains the IJh gene with a 
3’ multiple cloning site, to make the plasmid pLMS200. Using a similar approach, five 
other fusions of LFnTcdB were also constructed. Briefly, fragments encoding regions 
TcdB^‘^ ®° (nucleotides 1-1500), TcdB^'^^Vnucleotides 1-1260), TcdB*'*^ ® (nucleotides 1- 
510), TcdB^ -^^^  ^ (nucleotides 103-1668), TcdB^ '^^^  ^ (nucleotides 202-1668) were PCR 
amplified using primers listed in Table 1 and cloned into the BamHI site of pABII to 
make the plasmids pLMS201, pLMS202, pLMS204, pLMS205, and pLMS206 
respectively. Following ligation, the mixture was transformed into E. coli XL 1-blue 
(Stratagene, La Jolla, CA) and screened for inserts. Candidate clones were then 
transformed into E. coli BL-21(DE3) (Stratagene), BL-21 (DE3) Star (Invitrogen), or 
BL21 (DE3) RIL (Stratagene) for expression.
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Table 1. Primer Sequences For LFnTcdB enzymatic domain and deletion
mutants.
Carboxy-terminal deletions
Name__________ Primer sequence Amino Acids coded
for
Forward primer
pTBl ggccggggatccatgagtttagttaatagaaaa
Reverse primer
pTBJB02ba556 gccggggatccgtttcttaaatcagcttctatc 
pTBJB02ba gccggggatccgtttcttaaatcagcttctatc
TCDB420 ggcgccggatccttactcgctaatagctggatttaa
TCDB 170 ggcggcggatccttatgtgtttatcaaaaatgcatt
Amino-terminal deletions
Name__________ Primer sequence
1-556
1-500
1-420
1-170
Amino Acids coded
Forward Primers
LFnTbF 100 tacccgggcataatatgtcagagaatact
LFnTbF 200 tacccgggggtagaaataaagccttaaaaa
Reverse Primer
pTB JB02ba556 gccggggatccgtttcttaaatcagcttctatc
34-556
67-556
2 2
Site directed m utan ts
Site directed mutants were generated using Pfii Turbo DNA polymerase and the 
QuickChange mutagenesis approach (Stratagene). Oligonucleotides for generation of 
TcdBl-556c365s, TcdBl-556c36sw, and TcdBl-556wio2A are listed in table 2. Mutants 
were selected in E. coli XLl blue and confirmed by sequencing, followed by 
transformation into E. coli BL-21 Star for expression.
Expression and  isolation of recom binant RhoA. R a d . and  C dc42 su b s tra te s  and  
PA
RhoA, Racl, and Cdc42 were expressed from a pGEX2-T plasmid kindly provided by 
Dr. Alan Hall (University College London), and purified on a GST column. Briefly, IL 
cultures were induced with 1 mM IPTG for 4 h at 37°C. Cells were harvested by 
centrifugation, resuspended in 30 ml PBS and lysed by sonication in the presence of a 
protease inhibitor cocktail containing TLCK (Na-p-tosyl-l-lysine chloromethyl ketone), 
TPCK (L-l-tosyl-amide02-phenylmethyl chloromethyl ketone), and 
phenylmethylsulfonyl fluoride (Sigma Chemical). One milliliter of GST resin 
(Amersham Pharmacia) was washed three times in 1 ml PBS and incubated with the 
clarified cell extract shaking gently for 30 minutes at room temperature. The mixture 
was then added to a Bio-Rad poly prep column. The column was washed with 15 ml 
PBS and the fusion protein was eluted with 1.5 ml reduced glutathion elution buffer. 
Protein concentrations were determined by the Bradford assay (Bio-Rad Laboratories).
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Table 2. Primers for Site-directed Mutagenesis.
Name Primer sequence Amino Acids modified
Sense
C365S1
Antisense
C365S2
Sense
C365W1
Antisense
C365W2
gttttactattaaattgetagaatatgagtctttcaeag
etgtgaaagaetcatattctagcaatttaatagtaaaae
gttttaetattaaattgctaceatatgagtetttcaeag
ctgtgaaagactcatattggagcaatttaatagtaaaac
Cysteine 365 
to Serine
Cysteine 365 to 
Tryptophan
Sense
W102A1 aaaaatttacattttgttgctattggaggteaa
Antisense
W102A2 ttgaeetccaatageaacaaaatgtaaattttt Tryptophan 102 
to Alanine
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Recombinant PA was isolated from E. coli BL-21, harboring the plasmid, pSRB/ET-15b- 
PA (a generous gift from Steven Blanke). Expression was induced with lOOpM IPTG for 
12 h at 16°C, and the His-tagged protein was purified using His Bind Quick columns 
(Novagen) according to the manufacturer’s instructions. Imidazole was removed from 
the eluted protein using PDIO desalting columns (Amersham Pharmacia), according to 
the manufacturer’s instructions. Protein concentrations were determined by the Bradford 
assay (Bio-Rad Laboratories).
Isolation of LFnTcdB Fusion Proteins
LFnTcdBi.556, LFnTcdBi.500, LFnTcdBM20, LFnTcdBi.no, LFnTcdBss.ggg, LFnTcdB67-556 
LFnTcdBC365S, LFnTcdBC365W, and LFnTcdBW 102A were expressed in E. coli 
strain BL-21 Star grown in Luria broth (1.0% trypton (w/v), 0.5% yeast extract (w/v), and 
1.0% NaCl) supplemented with 75 pg/ml ampicillin. Expression was induced by the 
addition of lOOpM IPTG to cultures at a density between 0.6 and 0.8 ODgoo units. 
Following a 12 h induction at 16“C, cells were harvested by centrifugation and 
resuspended in His bind buffer (5mM imidazole, I50mM NaCl, 20mM Tris (pH 7.9)), 
and lysed by sonication. Both LFn and the LFnTcdB fusion proteins were isolated using 
a nickel resin column, following the manufacturer’s instructions (Novagen). Inclusion 
body purification was also performed according to the manufacturer’s instructions 
(Novagen). One change was made to the manufacturer’s protocol. LFnTcdB fusion 
proteins partially eluted in the recommended 60 mM imidazole wash buffer, so columns 
were washed vrith buffer containing 40 mM imidazole instead. As a second purification
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step, the protein was resolved on a high-resolution anion exchange (mono-Q) column at a 
flow rate of 1 ml/min in a buffer containing 20 mM Tris (pH 8.0). LFnTcdB fusions were 
eluted using a linear gradient from 0-100% NaCl and collected in 1 ml fractions. The 
fractions were analyzed by SDS- PAGE and by immunoblotting with an anti-His 
antibody (Santa Cruz Biotechnology Inc) and a HRP-conjugated secondary antibody.
Immunoblots were performed by loading 5 pi of candidate fractions onto a 10% SDS- 
acrylamide gel, and electrophoresing at 200 V for 40 min. The proteins were then 
transferred to a 0.45 pm nitrocellulose membrane (BioRad Laboratories) soaked in 
transfer buffer (190mM Glycine, 25mM Tris, .01% SDS, and 20% (v/v) methanol), using 
a BioRad transblot SD semi-dry transfer cell set at 20 V for 1 h. Following transfer, 
membranes were rinsed for 5 min in TBS buffer (20mM Tris (pH 8.0), and 0.8% sodium 
chloride) then incubated in a blocking solution containing 20 mM Tris (pH 8.0), 0.8% 
NaCl, 3% (w/v) non-fat dry milk for 1 hour at room temperature. The membrane was 
rinsed briefly in TBS containing 0.1% tween 20 (TBST) followed by a 1 h incubation 
with primary antibody (a His) (Santa Cruz Biotechnology, Santa Cruz, CA) diluted 
1/1000 in TBST. The blot was washed in 100 ml TBST with 5 changes of wash buffer 
for a total of 35 min. Horseradish peroxidase secondary rabbit antibody was diluted 
1/10,000 in blocking solution and allowed to incubate for 1 h at room temperature. The 
membrane was then washed as described above, and the blot was developed using 
luminol reagent (Santa Cruz Biotechnology) according to the manufacturer’s instructions. 
Blots were exposed to BioMax MR film (Kodak) for between 10 s and 5 min and the film 
was developed using GBX developer and fixer (Kodak) according to the manufacturer’s
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instructions. Fractions containing the fusion were pooled and tested for PA dependent 
cytopathic effects on CHO cells.
G lucosvlation a ssa y
CHO cell extracts and GST-RhoA, GST-Raci, and GST-Cdc42 were used as substrates 
to test glucosylation by TcdB^’^ ^^ . TcdB‘'^“ , TcdB*-^ °^, TcdB‘‘‘’°, TcdB^ '^^^^ and TcdB^’’ 
and TcdB. In order to prepare these extracts, CHO cells were grown in 75 cm  ^tissue 
culture flasks until confluent. The cells were then washed three times in ice cold PBS 
followed by mechanical removal (scraping) in the presence of lysis buffer (1 mM MgClz, 
1 mM MnCl2, 0.1 mM phenylmethylsulfonyl fluoride (PMSF) 10 pg/ml leupeptin, 25 
mM triethanolamine-HCl (pH 7.5)) similar to a previously described method (Just et al., 
1994). Cells were sonicated on ice 5 times for 30 s intervals and the resulting extract was 
centrifuged at 40k x g for 8 h. The supernatant was removed and concentrated in a 
Centricon concentrator with a 10 kD mwco (Millipore) until the extract reached a final 
volume of 0.5 ml.
CHO extracts (10 mg/ml), GST-RhoA, GST-Raci, or GST-Cdc42 (1 mg/ml) were added 
to a glucosylation mix containing 50 mM HEPES, 100 mM KCl, 1 mM MnClz, 1 mM 
MgClz 100 pg/ml BSA, 20 mM[^'‘C]UDP-glucose (308 Ci/mol; ICN Pharmaceuticals 
Inc) and 25 ng (96 finol) TcdB or 200 ng (~2 pmol) of the indicated LFnTcdB fusion in a 
final reaction volume of 20 pi. The reaction was incubated for two hours at 37"C and 
resolved by SDS-PAGE on a 15% acrylamide gel and imaged on a Packard electronic 
autoradiograph instant imager (Packard Instrument Company) similar to previously
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described methods (Just et al., 1994; Wagenknecht-Wiesner et al., 1997; Hof&nan et al., 
1997).
For differential glucosylation assays, HeLa cells (1 x 10 )^ were first treated with 325 
pmol of PA and 2.5 nmol of each fusion protein in a T-75 tissue culture flask with a final 
volume of 20 ml. Following 16 h treatments, cells were washed 3 X in ice-cold PBS, 
scraped and extracts were prepared as described above for glucosylation extracts.
Cytotoxicity a s s a y  an d  m o u se  lethality
CHO cells were plated at a concentration of 3 x 10'* cells/well in 96 well microtiter plates. 
The cells were allowed to adhere overnight and were then used to test the ability of 
LFnTcdB fusions to target cells in the presence and absence of PA. LFnTcdB fusion 
protein (6.25 pmol) was added to each well. A fixed amount of PA (3 pmol) was added 
to each of the PA containing wells. Each sample was performed in triplicate and 
cytopathic effects were determined by cell rounding.
In order to test for lethal effects of LFnTcdB*'^^  ^in BALB/c mice, ten fold dilutions of 
the fusion plus 3 pmol PA were added to CHO cells grown in a 96 well plate. The 
amount of fusion required to cause cytopathic effects in 50 percent of cells after 12 hours 
was determined to be the tissue culture infectivity dose (TCID50). A test group consisting 
of 4 mice was injected intravenously with 1,10,100, or 1000 TCID50 and 30 pmol of PA.
28
Actin Cvtoskeleton Staining
Human lung fibroblast cells were grown on glass coverslips in 24-well culture dishes in 
complete medium (minimum essential medium with high glucose [Gibco BRL], 200 U of 
penicillin/ml, and 200 pg of streptomycin/ml) until semi-confluent. To determine if PA 
plus LFnTcdB '^^^^ induces actin condensation similar to that induced by TcdB, the cells 
were treated with 2 TCIDsos TcdB or LFnTcdB^"^^  ^ and 3 pmol PA for four hours. 
Controls of PA alone and LFnTcdB in the absence of PA were also tested. The 
treated cells were fixed for 20 min in firesh 2% paraformaldehyde in 20 mM HEPES (pH 
7.5), with 150 mM NaCl. The cells were then washed once with PBS, permeabilized for 
10 min with 0.1% Triton X-100 in PBS at 4°C, then washed three more times with PBS. 
The cellular actin filaments were stained by incubating the permeabilized cells with a 
1:40 dilution of rhodamine phalloidin (Molecular Probes) for 30 min at room 
temperature, and washing three times with PBS. The cells were mounted in 
glycerohPBS/azide (8:1), and analyzed using an AX-70 microscope equipped with 
epifiuorescence optics (Olympus America, Inc.). A Spot cooled digital camera was used 
to capture the images (Diagnostic Instruments, Inc.).
H ydrolase a s sa y s
Glucosylhydrolase assays were carried out in a reaction mix containing 50 mM HEPES, 
100 mM KCl, 1 mM MnClz, 1 mM MgCb, 100 pg/ml BSA, 0.2 mM GDP, 40 pM 
[*'*C]UDP-glucose (303 Ci/mol; ICN pharmaceuticals Inc.) 100 pM UDP-glucose and 3 
pmol of TcdB or 10 pmol of each fusion protein in a total volume of 25 pi. The assay
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was allowed to incubate overnight at 37°C, similar to a previously described protocol 
[47], and the cleaved UDP-glucose was separated using AG1-X2 anion exchange resin. 
The column was washed with 4 ml ddHzO and 100 pi of each wash was counted in a 
liquid scintillation counter. One microliter of the reaction was collected before 
separation on the column and counted in a liquid scintillation counter. The percent of 
UDP-glucose cleaved was determined by using the following equations.
The total counts present in the hydrolase reaction were determined using the following 
equation:
C X  V = Tc
where C = counts in 1 pi of the original reaction, V = volume of the reaction (25 pi), and 
Tc = total counts present in the reaction.
The number of counts present in the wash was determined by the following equation:
Cwx Vw/Vc
where Cw = counts from the wash sample, Vw = volume of the wash (4,000 pi), and Vc 
= volume counted (100 pi).
Finally, the percentage of UDP-glucose cleaved was determined by dividing the counts 
from the wash (Cw) by the total counts present in the reaction (Tc).
Each value was determined by averaging duplicate reactions.
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Inhibitor a s s a y s
For the inhibitor assay, HeLa cells were plated in 96 well microtiter plates (3 x 10"^  
cells/well) and allowed to incubate overnight. The following day the cells were treated 
with 4 pmol of the appropriate LFnTcdB tusion plus 8.5 pmol of PA in a final volume of 
100 pi. The cells were cotreated with 80 finol of TcdB and observed for cytopathic 
effects. For sustained inhibition assays, 30 pmol of LFnTcdB’’^ ®^ plus 8.5 pmol of PA 
were added to cells in a final volume of 100 pi and allowed to incubate 30 min, at which 
point 20 finol of TcdB was added to the cells. Following the initial treatment, 30 pmol of 
LFnTcdB and 8.5 pmol of PA were added every 30 min for the first 90 min and every 
hour thereafter up to 12 h. Wells treated with TcdB alone were amended with an 
equivalent volume of buffer each time inhibitor treated cells were amended. The cells 
were observed for cytopathic effects for an additional 18 h. Similar competition assays 
were carried out using 2 pmol of TcsL or 300 ng of C. difficile culture supernatant. For 
inhibition assays with TcsL, cells were subjected to a brief acid-pulse, which enhances 
cytotoxic activity for this toxin. For the TcsL inhibition assay, cells were treated with 
TcsL via an acid pulse as previously described [48]. Briefly, LFnTcdB '^^ ®® was added to 
cells, allowed to incubate for 20 min then TcsL was added to cells and allowed to 
incubate for 5 min. The media was removed, replaced with media pH 4.0, and allowed to 
incubate for 5 min at which time the media was removed and replaced with pH 7.0 
media. The cells were amended with 30 pmol of LFnTcdB^‘^ °° and 8.5 pmol of PA. The 
inhibitor was added every 30 min for 90 min, then every hour afterward for 12 h. TcsL
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control wells were amended with an equal volume of buffer each time inhibitor was 
added and CPE were observed 16 h after treatment.
Protection of CHO cells expressing  LFnTcdB^'°^^
A CHO cell line was obtained from Dr. William Ortiz-Leduc and used to test for 
inhibition inside the cell. Briefly, this cell line was constructed by inserting a DNA 
sequence encoding the enzymatic domain of TcdB (amino acids 1-556) into the multiple 
cloning site of plasmid pGene/V5-His version B downstream of a Kozak sequence 
(Invitrogen). The plasmid was linearized with SapI and introduced into GeneSwitch- 
CHO cells (Invitrogen) by lipofection according to the protocol supplied with the 
LipofectAMINE PLUS Reagent Kit (Gibco Life Technologies). Transfected cells were 
selected for using Ham’s F12 media plus zeocin (300pg/ml) and hygromycin (lOOpg/ml). 
The cells were diluted and plated in 96-well plates. Only wells containing single foci 
were subcultured in 12-well plates using selective media. GeneSwitch- 
CHOpGene/TcdBl-556, a lineage of transfected cells showing nearly 100% rounding in 
24 h in the presence of mifepristone, was identified and chosen for the experiments 
reported herein.
GeneSwitch CHO cells transfected with pGene TcdB '^^^  ^were plated at 3 x 10"* cells per 
well in 96 well plates in Ham’s F-12 media. Cells were allowed to adhere for 6 hours 
then supplemented with 300pg/ml zeocin and lOOpg/ml hygromycin. Six hours after the 
addition of antibiotics, the cells were treated with mifepristone (lO’^ M) in order to induce
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expression of the TcdB enzymatic domain. Two hours after the induction, before 
cytopathic effects were observed, 8.5 pmol PA and 30 pmol LFnTcdB^'^°° or an equal 
volume of buffer (control wells) were added to cells. The treatments were repeated every 
30 min for up to 6 hours and the percent CPE were recorded for duplicate wells with and 
without PA, LFnTcdB^'^”®.
In vitro Inhibition experim ents
In vitro glucosylation was carried out in a reaction mix as described above for 
glucosylation assays. TcdB (25 finol) was added to the reaction mix containing HeLa 
cell extract (1.8 mg/ml) in a final reaction volume of 25 pi. LFnTcdB^'^°° (5.2 pmol) was 
added to one assay while an equal volume of buffer was added to a second assay. The 
reactions were incubated for 25 minutes and run on a 15% polyacrylamide gel. The gel 
was dried and exposed to film for 5 days.
Differential glucosylation of HeLa ex tracts  from cells co trea ted  with LFnTcdB^~^°° 
and  TcdB
Hela cells were plated in T-25 tissue culture flasks and allowed to incubate until semi­
confluent. LFnTcdB (26 nmol) and PA (30 pmol) were added to cells and allowed to 
incubate for 30 minutes. TcdB (190 finol) was added to the cells in the presence and 
absence of the inhibitor. The cells were allowed to incubate until those lacking inhibitor 
became 40% round (approximately 3 hours). Extracts were then prepared and used as a 
source of substrate for in vitro glucosylation assays.
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V8 o ro tea se  digestion
LFnTcdB*’^ ^^ , LFnTcdB^^"^"^, and LFnTcdB^^^^^ (2 p,g) were digested with 10 ng V8 
protease for 1 or 2 h. The digestions were run on a 15% acrylamide gel and 
immunohlotted using a primary a  His antibody according to the protocol described 
previously.
34
RESULTS
Tim e C ourse  of cvtosolic entry for TcdB and TcsL
In order to determine the time course of cellular entry for TcdB, CHO cells were treated 
with TcdB followed by the addition of the lysosomotropic inhibitor bafilomycin A1 at 10 
min intervals. Bafilomycin blocks acidification of the endocytic vesicle preventing TcdB 
from translocating into the cytosol and gaining access to cellular targets. Cells were 
partially protected from TcdB induced cytopathic effects by the addition of Bafilomycin 
A1 up to 50 minutes following TcdB treatment. Small amounts of TcdB began to enter 
the cytosol after 40-50 min indicated by the 40% CPE observed at 8 hours post treatment, 
however, CPE comparable to the TcdB control did not occur until 60 min post treatment 
(Figure 8). A similar experiment was performed using a related LCT, TcsL. TcsL 
treated cells were still 60 % protected from CPE when bafilomycin was added even 120 
min after the addition of toxin (Figure 9). This indicates that TcdB is much more efficient 
at binding and entering into CHO cells than TcsL.
Purification of the  TcdB enzym atic dom ain fused  to LFn (LFnTcdB^'^^^)
The amino-terminal 556 amino acids of TcdB, which encompasses the glucosylating 
domain of TcdB, was fused to the amino-terminal 254 residues of LF (LFn), expressed in 
E. coli BL-21 (DE3) and purified using an amino terminal hexa-His tag. This fusion 
consistently eluted at 60-80 mM imidazole compared to LFn, which eluted at 250 mM
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Figure 8. Bafilomycin A1 inhibition of TcdB Cytosolic Entry.
200 finol of TcdB was added to CHO cells in a 96 well plate.
Bafilomycin (5 x 10' M) was added eveiy 10 minutes following 
TcdB treatment. Samples were performed in triplicate and error 
bars mark the standard deviation. CPE were recorded after 8 and 
16 hours. B, buffer control; TB, TcdB alone; I, inhibitor only.
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Figure 9. Bafilomycin A1 inhibition of TcsL cytosolic entry.
TcsL (1 pmol) was added to CHO cells plated in a 96 well plate. 
Bafilomycin A1 was added to cells at the indicated times after TcsL 
treatment. CPE were recorded after 16 hours. B, buffer control; 
LT, TcsL alone; I, inhibitor alone. Samples were performed in 
triplicate and error bars mark the standard deviation.
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Figure 10. Nickel Column Purification of LFnTcdB^ '®®® and LFn. A. LFnTcdB^’®®^ purification Lane 1, 
molecular weight markers; Lane 2, flow through; Lanes 3-8; washes with indicated concentration imidazole. B. 
LFnTcdB^ '®^ ® purification using the standard 60 mM wash buffer and 1 M elution buffer. C. LFn purification 
Lane 1, molecular weight markers; Lane 2, flow through; Lanes 3-7; washes with indicated concentration 
imidazole. LFnTcdB*'^^® eluted at 60-80 mM imidazole, whereas LFn eluted at 250 mM imidazole. Arrows 
indicate the correct size of the fusion and LFn
imidazole suggesting the His tag may only be partially exposed in the LFnTcdB fusion 
(Figure 10). Furthermore, protein yields were about 1-2 mg/L of purified protein and co- 
purifying truncated forms were common.
Several methods were employed to enhance expression of LFnTcdB The fusion 
protein was expressed at 16”C. Some target proteins express more efficiently at lower 
temperatures and it has been suggested that this phenomenon is a result of increased 
solubility of the target protein at the lower temperature. Additionally, many cytosolic 
proteases are active at 37°C, but inhibited at 16°C, and the lower temperature may 
improve expression of the target protein by preventing proteolysis. An immunoblot of 
purified LFnTcdB '^^^^ after a 12 h induction at 16°C did indicate that truncated forms of 
the purified fusion protein were reduced compared to the same protein isolated from a 
37”C induction (Figure 11). In order to determine if some of the fusion may be insoluble 
when expressed at 37“C, a His-tag purification was performed by solubilizing the 
sonicated cell pellet in nickel column buffers containing 8 M urea. No fusion protein 
eluted from a column performed under denaturing conditions but all the protein was 
recovered from the soluble fraction indicating the protein was not present in inclusion 
bodies.
It has been reported that many genes from gram-positive organisms contain codons that 
are rare to E. coli and therefore result in early termination of transcripts and low protein 
yields when over expressed in E. coli [49]. As an attempt to improve expression of the 
LFnTcdB^"^^  ^fusion protein, the BL-21 (DE3) RIL strain was analyzed. This strain
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Figure 11. Immunoblots of Purified LFuTcdB^ "^ ®® Expressed at 37°C 
and 16°C. Lane 1, BL-21 (DE3) expression at 37°C; Lane 2, BL- 
21 (DE3) expression at 16°C.
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contains a plasmid that encodes for extra copies of the argU, ileY, and leuW tRNA.
These tRNA recognize the AGA/AGG, AU A, and CUA codons, respectively. These are 
codons common to organisms with AT rich genomes such as Clostridia but rare in E. coli 
[50]. When the sequence that encodes for the first 556 amino acids of TcdB was 
examined, it was determined that AT bases accounted for 70% of the residues and 16 
AGA/AGG, 21 AU A, and 2 CUA codons were present indicating that using this strain 
may improve expression of LFnTcdB*'^^ .^
A second strain BL-21 (DE3) Star was also analyzed. This strain has a truncated RNase 
E gene and has been shown to stabilize mRNA, which may be susceptible to degradation 
in the BL-21 (DE3) strain. As an additional attempt to improve the amount of full length 
protein expressed, the plasmid encoding for rare tRNA was isolated from the BL-21 
(DE3) RJL strain, transformed into BL-21 (DE3) Star to make the strain BL21 (DE3) 
Star-RIL. LFnTcdB '^^^^ was expressed in BL21 (DE3) RIL, BL21 (DE3) Star, and BL- 
21 (DE3) Star-RIL strains and purified using the standard protocol. Immunoblots were 
performed on freshly isolated LFnTcdB*’^ ^^  expressed in each of these strains. As can be 
seen in figure 12, expression in BL-21 Star resulted in a decrease of truncated protein, 
while the BL-21 RIL strain did not. Furthermore, transformation of BL-21 star with the 
RIL plasmid did not further reduce the presence of truncated proteins. Based on these 
initial studies, an approach of expressing the fusion protein at 16°C in the BL-21 Star 
strain was selected. Additionally, a lower imidazole concentration (40mM instead of the
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Figure 12. Immunoblots of Purified LFnTcdB^' 
Expression in Different Strains of E. colL.
Lane 1, BL-21 (DE3); Lane 2, BL21 RIL; Lane 3, 
BL21 Star; Lane 4, BL-21 Star RIL. The full 
length fusion in indicated by an arrow.
42
recommended 60mM) was used for the nickel column wash buffer to avoid partial elution 
of the fusion in the wash step.
A nalysis of th e  enzym atic  activity of LFnTcdB^'^^^
The LFnTcdB '^^^  ^fusion was tested for enzymatic activity and compared with the activity 
of native TcdB. The first step in substrate modification is hydrolysis of the cosubstrate 
UDP-glucose. Hydrolysis was tested for by mixing 3 pmol TcdB or 10 pmol LFnTcdB^' 
with [’'*C]UDP-glucose in a reaction buffer, incubating at 37°C overnight and 
separating the cleaved glucose using an AGI X-2 anion exchange column. The percent 
hydrolysis of cosubstrate was determined by washing the column with water and 
counting the cleaved [^ '‘CJglucose in a liquid scintillation counter. Ten pmol LFnTcdB^' 
maintained hydrolysis activity equivalent to 25% of the activity of the 3 pmol native 
TcdB (Table 3).
Using purified recombinant substrates (GST-RhoA, GST-Raci, and GST-Cdc42) 
substrate specificity was determined for LFnTcdB*'^^  ^by in vitro glucosylation. Native 
TcdB and LFnTcdB*'^^  ^showed similar substrate specificity and had the greatest activity 
with Cdc42, followed by Rac, and then RhoA (Figure 13).
To determine the rate of intoxication of CHO cells, we treated with either 100 finol of 
LFnTcdB '^^^® plus PA or 100 finol of TcdB and followed over time for CPE. It took 
approximately 2 h longer for cytopathic effects to be observed vyith the LFnTcdB '^*^^
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Tables. UDP-Glucosylhydrolase activity of LFnTcdB^ '®®®. A
reaction mixture containing 3 pmol of TcdB or 10 pmol of 
LFnTcdB*'^^  ^was incubated overnight in the presence of 
UDP-glucose. The reaction mixture was passed over an anion 
exchange column that specifically binds UDP-glucose, but not 
cleaved glucose. The wash was counted in a scintillation counter, 
and hydrolysis expressed as a percent of total [*'*C]UDP-glucose 
present before separation. Each value is an average of duplicate 
assays
Toxin/Fusion % Hydrolysis +/-
TcdB 27.7 0.64
LFnTcdB 1-556 6.9 1.02
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Cdc42 -H- ++
Figure 13. Glucosylation activity of TcdB and LFnTcdB^ '^ ®^ . A.
Recombinant substrates RhoA, R ad , and Cdc42 (20 ^g) were used in an in 
vitro glucosylation assay with 25 ng TcdB or 200ng LFnTcdB . B. In 
order to determine the minimum amount of substrate required for modification 
under these conditions, substrate concentrations were varied from 3-14 q.g. 
Both the fusion and TcdB preferred Cdc42 as a substrate followed by Rac, and 
then RhoA. (++) indicates that the substrate was modified by the fusion and by 
TcdB.
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Figure 14. Time-course of CPE for TcdB and LFnTcdB^ "^ ®* plus FA. CHO cells 
were plated in 96 well plates (3 x 10"^  cells/well), allowed to adhere overnight, and 
treated with TcdB or LFnTcdB 1-556 and PA. CPE were determined by cell rounding. 
Each sample was performed in triplicate. Error bars mark the standard deviation from 
the mean.
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fusion than with native TcdB (Figure 14). Additionally, a dose curve of CPE was 
performed with TcdB and LFnTcdB It was determined that 100 fold more of the 
fusion was required to elicit the same CPE as TcdB (Figure 15). The slower cytopathic 
effect of LFnTcdB '^^^^ on CHO cells is likely due to the reduced hydrolase activity of the 
fusion compared to native TcdB although an effect of differences in binding and cellular 
entry on toxicity can not be excluded.
In order to determine if LFnTcdB had the same effect as TcdB on actin organization, 
human fetal lung fibroblast cells were treated with LFnTcdB*'^^  ^plus PA or TcdB for 4 
hours followed by staining with rhodamine phalloidin. TcdB and LFnTcdB*'*^  ^ both 
caused actin condensation in contrast to PA/LFn alone (Figure 16).
The TcdB Glucosylation Domain Confers Lethality
Taking advantage of the PA/LFn delivery system, LFnTcdB*'^^® was tested for lethality 
in BALB/c mice. A test group consisting of 4 mice was injected intravenously with 1, 
10, 100, or 1000 TCID50 of LFnTcdB '^^^^ plus PA resulting in 100% lethality of mice 
injected with 1000 TCID50 of LFnTcdB*'^^^ and PA. Mice injected with similar amounts 
of PA and LFn were unaffected indicating that the glucosylating domain of TcdB is 
sufficient to cause death in BALB/c mice (Table 4).
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Fteure 15. Dose-Curve Response of TcdB and LFnTcdB^' 
plus PA CPE. CHO cells were plate (3 x lO'* cells/well) 
in 96 well plates and allowed to adhere overnight. The 
following day the cells were treated with the indicated 
amounts of TcdB or LFnTcdB*’^ ^^  Plus PA. CPE were 
determined by cell rounding, and were recorded 12 h after 
treatment.
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Figure 16. Actin Staining. Fibroblast cells were grown on glass 
coverslips until semiconfluent and treated with TcdB or 
LFnTcdB '^^^^ and PA. Cells were stained with Rhodamine 
phalloidin to visualized F-actin. Panel A, Untreated; Panel B, 
TcdB; Panel C, PA-LFnTcdB*'^^^
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Table 4. Lethal Effects of LFnTcdB^ '®®^ . Female Balb/c miee (4/group) were injected intravenously with increasing 
TCID50 doses of LFnTcdB '^^^  ^plus 30 pmol of PA. The correlating TCID50 protein concentrations are shown in column 2. 
Mice were followed for 18 h after treatment.
TCID50 LFnTcdB^ ®^^ % Lethality (per 4 mice)
1 0.01 pmol 0%
10 0.1 pmol 0%
100 1.0 pmol 0%
1000 10 pmol 100%
o
Construction. Purification, and Characterization of Carboxv-terminal Deletions of 
LFnTcdB1-556
Since the LFnTcdB '^^^^ fusion was determined to have similar, although slightly reduced, 
glucosylation activity as TcdB, a series of mutants of this fiision were generated to 
further characterize this enzymatic domain. Initially, three fusions with deletions at the 
carboxy-terminus (LFnTcdB '^^°°, LFnTcdB*^^® and LFnTcdB*'*^*’) were generated by 
PCR amplifying each fragment and cloning into the BamHl site of pABII. These fusions 
were void of glucosylation activity (Figure 17). Since these enzymatically-attenuated 
mutants may still interact with, but not modify substrate, each of the carboxy-terminal 
deletions was tested for the ability to inhibit toxicity of native TcdB. Each fusion was 
added to cells in 96 well plates along with PA and allowed to incubate for 30 minutes, 
followed by the addition of TcdB. Cytopathic effects were followed over time and it was 
determined that in the presence of LFnTcdB*‘^ °° or LFnTcdB*"^^°, CPE were delayed for 
2 hours suggesting these fusions act as inhibitors of TcdB, while LFnTcdB*’*’® had no 
inhibitory effect on toxicity of TcdB (Figure 18). To test whether or not the eventual 
death of cells in the presence of inhibitor could be due to breakdown of the inhibitor 
within cells, an inhibition assay was set up where inhibitor continued to be added at 30 
minute intervals up to 12 hours after the addition of TcdB. Fifty percent of cells treated 
with TcdB in the presence of the LFnTcdB*"^ ®® inhibitor and PA were still protected 36 
hours after TcdB addition (Figure 19).
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RhoA R a d Cdc42
Figure 17. Glucosylation of recombinant substrates RhoA, R ad, 
and Cdc42. Lane 1, TcdB; Lane 2, LFnTcdBl-170; Lane 3, LFnTcdB 1- 
420; Lane 4, LFnTcdB 1-500; Lane 5, LFnTcdB 1-556.
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Figure 18. Delayed CPE of TcdB. In the presence of LFnTcdB^ "*^ ** and PA or LFnTcdB '^^"" and 
PA, TcdB CPE were delayed for approximately two hours compared to TcdB alone or TcdB, 
LFnTcdB '^*’® and PA. CPE were determined by cell rounding.
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Figure 19. Inhibition of TcdB CPE by the continued addition of LFnTcdB^^"". HeLa cells were plated in a 96 
well plate (3x10^ cells/well). The following day the cells were treated with TcdB and LFnTcdB^ '^ ®'* plus PA. During 
the course of the assay LFnTcdB*’^®® and PA were added at 30 min intervals for 12 h. The cells were followed for 30 
hours and visualized for CPE as determined by cell rounding.
Inhibition of C PE  from C. difficile su p e rn a tan t
The therapeutic value of these inhibitors will depend upon their ability to inhibit TcdA as 
well as TcdB since both toxins are important to the disease process. For this reason, we 
tested the ability of LFnTcdB to prevent cell rounding when treated with supernatant 
from a C. difficile culture. HeLa cells were cotreated with PA, LFnTcdB^‘^ °° and protein 
from a C. difficile culture supernatant. The cells were amended with PA, LFnTcdB^’^ °° 
every 30 min for the next 12 hours and CPE were determined by cell rounding. Even 28 
hours after treatment with the C. difficile culture supernatant, 50 percent of cells were 
protected from toxin induced cell rounding (Figure 20). Since TcdB is 1000 fold more 
cytotoxic than TcdA and LFnTcdB*'^°° was not tested for the ability to inhibit the effects 
of purified TcdA, we cannot conclusively say this protein acts as an inhibitor of TcdA, 
but it does protect cells from CPE induced by C  difficile culture supernatant.
While LFnTcdB was void of hydrolase and transferase activity and showed no 
cytotoxicity on HeLa or CHO cells, this fragment when administered to cells over a 
prolonged period of time induced reversible effects on cell shape. That is cells began to 
condense and take on a more rounded appearance. These cells did not round completely, 
and when the media was replaced with fresh media, the cells returned to their normal 
appearance (data not shown).
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Figure 20. Inhibition of CPE from C. difficile supernatant by the continued addition of LFnTcdB*'®*’*’. HeLa cells (3 
xlO^ cells/well) were plated in a 96 well plate and allowed to adhere overnight. The following day cells were treated with 
supernatant from a C. difficile culture, or supernatant and LFnTcdB*'®*’*’ plus PA. LFnTcdB*' *** plus PA in the absence of 
supernatant was added as a control. During the course of the assay LFnTcdB*'®*’*’ and PA were added at 30 min intervals for 
12 h. The cells were followed for 30 hours and visualized for CPE as determined by cell rounding.
Inhibition of C. sordellii TcsL
In order to determine if LFnTcdB was able to inhibit the activity of other LCTs, TcsL 
was purified from C. sordellii and introduced into cells via an acid pulse. PA and 
LFnTcdB '^^°° were added to cells immediately following the pH pulse and every hour 
thereafter. Cells were observed for CPE over the next 16 hours. Over 80 percent of cells 
treated with PA LFnTcdB were protected from TcsL toxicity, while only 40 percent 
of cells treated with TcsL alone survived the treatment indicating that LFnTcdB can 
also inhibit toxicity by TcsL (Figure 21).
Inhibition Inside the Mammalian Cell
Inhibition most likely occurs inside the cytosol of cells, however since the receptor for 
TcdB has not been identified, competition for receptor as a means of inhibition could not 
be excluded. In order to address the question of whether the inhibition occurs inside the 
cell, a CHO cell line expressing TcdB '^^^  ^under the control of an inducible promoter was 
utilized. Expression of the enzymatic domain was induced with mifepristone, and two 
hours later, before the onset of cytopathic effects, the media was removed and replaced 
with fresh media for control wells or media containing LFnTcdB*'^ *^ ® and PA for test 
wells. The cells were amended every 30 min for six hours and CPE were recorded in the 
presence and absence of the inhibitor. LFnTcdB*'^°° was able to delay CPE by at least 2 
hours compared to controls with no inhibitor present (Figure 22). These results indicate 
that the competition was occurring inside the cell.
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Figure 21. LFnTcdB inhibition of TcsL cytopathic effects. HeLa cells were plated in 96 well plates 
(3 X lO'* cells/well), allowed to adhere overnight, and treated with L F n T c d B p l u s  PA 30 minutes prior 
to TcsL treatment. TcsL cell entry was mediated via an acid pulse and cells were amended with PA and 
LFnTcdB'"^ ®® immediately and at 30 min intervals for up to 12 hours. Cells were observed for CPE 
(determined by cell rounding) 18 hours after toxin treatment.
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Figure 22. Inhibition of CPE in CHO cells expressing the enzymatic domain of 
TcdB. A CHO cell line transfected with TcdB*'  ^under the control of an inducible 
promoter was induced with mifepristone. 2.5 hours after induction, before CPE were 
observed, LFnTcdB*'^ ®** plus PA was added to cells and was added every 30 minutes 
thereafter up to 7 h. Cells were observed and CPE, as determined by cell rounding, 
were recorded at each of the indicated time points.
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In vitro Inhibition of TcdB
If LFnTcdB '^^°° inhibits the activity of TcdB by interacting with substrate, then inhibition 
should be observed in an in vitro assay. Glucosylation assays using HeLa extracts as 
substrate were performed in the presence of LFnTcdB*'^®” or an equivalent amount of 
buffer. This assay was performed in triplicate and in vitro glucosylation was reduced by 
25.4% +/- 6.25 in assays with inhibitor present compared to assays with no inhibitor 
added (Figure 23).
In vitro glucosylation of substrates prepared from cells treated with TcdB and 
Inhibitor
Glucosylation assays were performed on extracts prepared from cells treated with TcdB 
or cotreated with TcdB and LFnTcdB If substrate was protected in cells where 
inhibitor was present, then it should be accessible to TcdB in the subsequent in vitro 
assay. Interestingly, a target was found that was protected from modification in cells 
treated with the toxin and inhibitor, but not TcdB alone (Figure 24). This target was 
larger than the predicted size for Rho, Rac, and Cdc42. The target may be a yet 
unidentified substrate of TcdB, or it may be an SDS-resistant protein complex containing 
Rho, Rac, or Cdc42.
Time-course of Inhibition
LFnTcdB^'^°° and PA were added to cells either prior to or subsequent to TcdB treatment. 
Cells were amended with fresh inhibitor at 1 h intervals following addition of TcdB (for
60
1Figure 23. In vitro competition. Glucosylation assays were 
performed with TcdB (Lane 1) or TcdB in the presence of LFnTcdB 1- 
500 (Lane 2). The reactions were incubated for 25 minutes and the 
gels were exposed to film for 5 days. This is a representative sample 
of triplicate assays.
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Figure 24. Differential Glucosylation of Extracts Prepared from Cells Treated With TcdB 
or TcdB plus Inhibitor. Hela cell extracts were prepared from treated cells and tested for 
glucosylation in vitro. 1, untreated; 2, TcdB treated; 3, TcdB, LFnTcdB '^^ '^^and PA treated. All 
extracts were treated with TcdB in vitro. A target of about 40kD was glucosylated in extracts 
from untreated cells or in extracts prepared from cells treated with TcdB and inhibitor but not in 
extracts prepared from TcdB treated cells.
cells pretreated with inhibitor) or 1 h intervals follovdng inhibitor addition (for post­
treatment with inhibitor). Cells were amended with inhibitor for 8 hours at which time 
CPE were determined. We found that this inhibitor was able to block the effects of 
TcdB on cells when added as much as 40 minutes before toxin treatment or up to 40 
minutes following TcdB treatment (Figure 25).
Construction. Purification and  A nalysis of Amino-term inal D eletions and  site- 
Directed M utants of th e  TcdB Enzym atic Domain F used  to  LFn
In order to further characterize the TcdB enzymatic domain, and determine the minimal 
region required for glucosylation activity, amino terminal deletions were constructed. 
Fragments containing small deletions at the amino-terminal end of the enzymatic domain 
of TcdB have not been previously characterized. Cloning PCR products into the 
BamHI/XhoI site of pABII generated the fusions LFnTcdB^ '^^^  ^ and LFnTcdB^ '^^^ .^ 
These fusions were tested for glucosylation activity, and it was determined that deleting 
as little as 35 residues from the amino terminal end of the TcdB glucosylation domain 
abolished enzymatic activity. This was determined to be due to a loss of 
glucosylhydrolase activity (Table 5).
Three site-directed mutants were generated in order to further characterize the TcdB 
enzymatic domain. Deletions of the enzymatic domain most certainly result in 
conformational changes. These changes cannot be identified using protease digestion 
since truncated proteins will result in different digestion patterns regardless of 
conformation. The TcdB enzymatic domain contains a single cysteine residue at position
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Figure 25. Inhibition of TcdB cytopathic effects prior to or following 
TcdB treatment. Hela cells (3 x 10 ) were plated in a 96 well plate and 
allowed to adhere overnight. The following day cells were treated with 
L F n T c d B a t  the indicated time-points, either prior to or following TcdB 
treatment. Cells were amended with inhibitor every hour following the 
initial treatment and CPE were scored (as determined by cell rounding) 
after 8 hours. Each value is an average of two independent samples and 
error bars mark the standard deviation from the mean.
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Table 5. Glucosylhydrolase Activity of LFnTcdB Amino-Terminal 
Deletion Mutants. Hydrolase Activity is Expressed as a Percentage of 
Total UDP-Glucose Present In the Reaction. 9 pmol of each fusion or 3 
pmol of TcdB were added to the indicated reaction. Values represent an 
average of duplicate assays.
Toxin/Fusion % Hydrolysis 4- / -
TcdB 24.6 1.22
LFnTcdB35-556 0 0.11
LFnTcdB67-556 0 0.24
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365 in the putative substrate recognition region. Pilot studies using N-ethylmaleimide 
indicated that cells could be protected from CPE by modification of this residue. To test 
whether or not we may be able to interfere with substrate recognition by modifying this 
residue, conservative (C365S) or non-conservative (C365W) mutations of cysteine 365 
were constructed using a site-directed mutagenesis kit. One previously characterized 
mutant W102A, found to be defective in UDP-glucose binding [51], was constructed in a 
similar fashion. These site-directed mutant fusion proteins were tested for 
glucosylhydrolase activity, glucosylation activity and CPE on HeLa cells. It was 
determined that only the C365S mutant retained glucosylation and cytotoxic activity 
comparable to LFnTcdB*'^^^ (Figure 26).
H ydrolase Activity of S ite-directed M utants of th e  TcdB Enzvm atic Domain
Each of the site-directed mutants was tested for the ability to hydrolyze [^ "^ C] UDP- 
glucose. It was determined that each of the proteins that were inactive for glucosylation 
was also void of glucosylhydrolase activity (Table 6).
V8 P ro tea se  Digestion
In order to determine if conformational changes might be responsible for the loss of 
hydrolase activity in the site-directed mutants, LFnTcdB '^^^ ,^ LFnTcdB^^^^^, and 
LFnTcdB '^®^"  ^were digested with V8 protease and the digestion profiles were compared 
by immunoblot using an antibody to the amino-terminal His-tag. The digestion patterns
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Cdc42
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Fusion (ng) LFnTcdB 1-556 LFnTcdBC365S LFnTcdBC365W LFnTcdBW102A
150 90% 88% 13% 12%
15 50.50% 46% 15% 15%
1.5 12.50% 14% 14.50% 13%
Figure 26. Glucosylation and CPE of LFnTcdB Site-Directed Mutants. A. Glucosylation assays were 
performed using recombinant RhoA, Racl, and Cdc42 as substrate. Lane 1, LFnTcdB' '^'®^ ;^ Lane 2, 
LFnTcdB*^ ^®^ ''^ ; Lane 3, LFnTcdB*^^^^ ;^ Lane 4, LFnTcdB*'^^ .^ B. CPE were determined using HeLa cells 
plated in 96 well plates (3 x 10‘*cells/well) using a fixed amount of PA (700 ng) and the indicated amount 
of each fusion. CPE were determined after 90 minutes. Values are an average of duplicate assays.
Table 6. UDP-Glucose Hydrolysis of LFnTcdB Site Directed Mutants.
Three pmol of TcdB or 9 pmol of each fusion were added to the indicated 
reactions. Hydrolysis is expressed as a percent of total UDP-glucose present 
before separation on an anion exchange column that specifically binds UDP- 
glueose.
TcdB/Mutant % Hydrolysis +/-
TcdB 25.3 0.87
LFnTedBC365s 6.2 3.10
LFnTcdB^365w 1.23 0.51
LFnTcdB'^i02A 1.02 0.1
6 8
indicate that large conformational changes had not occurred as a result of the 
substitutions (Figure 27).
Differential Glucosylation
A total of 8 mutants of the enzymatic domain of TcdB were generated (summarized in 
Figure 28) and characterized for in vitro activity and CPE on tissue culture cells. In vitro 
protein assays often fail to mimic intracellular conditions and may not accurately reflect 
the activity of proteins inside cells. In order to determine if these fusions retained 
glucosylation activity in vivo, each of the fusions were used to treat HeLa cells. After 
prolonged incubation (16 h) with the indicated fusion, extracts were prepared and used as 
substrate for glucosylation assays with native TcdB. TcdB was still able to target 
substrate in extracts prepared from glucosylation defective mutants, but was reduced in 
the ability to glucosylate targets previously treated with glucosylation active fragments. 
RhoA (22kD), slightly larger than Rac or Cdc42 (20kD), was not as effectively modified 
in tissue culture and was still partially accessible in the subsequent in vitro assay (Figure 
29).
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Figure 27. V8 Protease Digestions. Proteins were digested for 0, 1 or 2 
hours as indicated. 1, LFnTcdB^^^^^; 2, LFnTcdB^'^^^ 3, LFnTcdB'^‘“^ ;^ 
4, LFnTcdB^^^ '^^; 5, LFnTcdB^'^^^ 6, LFnTcdB^ '^^^^; 7, LFnTcdB^^^^^; 
8, LFnTcdB'-^^^; 9, LFnTcdB'^^”^ .^ Proteins were analyzed by SDS-PAGE 
and immunoblotting with anti-His antibody.
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Figure 28. Summary of LFnTcdB Deletion and Site-Directed Mutants.
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Figure 29. Differential glucosylation. Hela cells were 
treated with each of the indicated fusion proteins and PA for 
16 hours. Extracts were then prepared and tested for in vitro 
glucosylation by native TcdB.
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In Vivo Inhibition of TcdB
Since several of the amino-terminal deletion mutants and site-directed mutants were void 
of glucoslylation and glucosylhydrolase activity, they were tested for the ability to inhibit 
CPE of TcdB in tissue culture cells. Cells were cotreated with TcdB and each of the 
LFnTcdB mutant proteins plus PA. From Figure 30 it is obvious that each of these 
inhibitors, the amino-terminal deletions, and the site-directed mutants with substitutions 
in the cosubstrate-binding region, or the putative substrate recognition region inhibited 
toxicity by TcdB.
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Figure 30. Inhibitory Capacity of LFnTcdB Amino-Tcrminal and Sitc-Dircctcd Mutants. Hela cells 
were plated in 96 well plates and were treated with PA plus the indicated fusion protein and TcdB. CPE 
were recorded for each condition at 1 h intervals for 7 h. Each sample was performed in triplicate and error 
hars mark the standard deviation from the mean.
DISCUSSION
Five LCTs are produced by three different species of clostridia and all are relevant to 
disease in both humans and animals. C. difficile is responsible for CD AD, while C. novyi 
and C. sordellii have been implicated in gas gangrene infections. The toxins produced by 
these organisms are largely responsible for the diseases they cause.
The glucosylation activity of TcdB has not previously been directly linked to death of an 
animal. Curiously, TcdA, which encodes a similar enzymatic activity but is 1000-fold 
less cytotoxic than TcdB, has a similar lethal dose [52]. Additionally, TcdA and TcdB 
are unusually large toxins of which, the majority of residues are completely 
uncharacterized, thus introducing the possibility that other enzymatic activities that 
contribute to death are encoded in the full-length toxins. Taking advantage of the PA- 
LFn delivery system, we were able to demonstrate, for the first time, that the 
glucosylation domain of TcdB is sufficient to cause death in an animal model.
Although all LCTs share a similar enzymatic activity, they vary in their ability to cause 
cytopathic effects on cells. TcdB is more cytotoxic than TcdA or TcsL and has been 
reported to have a 1000 fold greater enzymatic activity than TcdA when tested on 
substrates RhoA, Racl, and Cdc42. Interestingly, TcdB and TcsL have been reported to 
have a similar hydrolase activity and an equal ability to modify the substrate Rac,
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suggesting the greater toxicity of TcdB compared to TcsL is due to the slower cell entry 
of TcsL rather than reduced enzymatic activity [53]. The results we obtained using 
lysosomotropic agents to follow the cellular entry of TcdB and TcsL confirmed that TcsL 
does enter HeLa cells more slowly than TcdB thus accounting for the slower CPE of 
TcsL.
This work has demonstrated the effectiveness of using PA, LFn to deliver fragments of 
LCTs to the cytosol of cells. Deletion, site-directed mutants and domain swapping 
experiments have begun to map regions of these toxins important for substrate 
recognition as well as hydrolase and transferase activities [12, 37, 51]. Until now these 
experiments were very cumbersome and required microinjecting large amounts of the 
mutant proteins into mammalian cells. The LFnTcdB fusions described herein will serve 
as a model for construction of LFn fusions of the enzymatic domains of other LCTs. 
These tools will prove invaluable for structure function studies of LCTs as has already 
been demonstrated herein using the enzymatic domain of TcdB.
Another advantage of using the PA-LFn system to characterize LCTs, is the ability to 
identify the effects of mutant forms of these toxins within cells. The mutant forms of the 
TcdB enzymatic domain have been useful for detecting in vivo inhibition and for 
determining the effects of this inhibitor within cells (ie. preventing modification of 
targets). Additionally, the inhibitor provided a unique tool for dissecting the events 
occurring following membrane translocation. While lysosomotropic inhibitors have 
proved useful for following cell entry by bacterial toxins, tools to analyze events
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following translocation have not been previously reported. Since these inhibitors were 
shown to block toxin activity within the cytosol, this provided an opportunity to analyze 
an intracellular toxin after membrane translocation. Our data show that addition of 
inhibitor at 40 minutes after TcdB treatment is still able to protect cells from CPE (Figure 
26). Taking into account the 20 minutes that it takes anthrax toxin to enter the cytosol, 
we can conclude that CPE can be blocked in the cytosol for up to 60 min after 
extracellular toxin treatment. Furthermore, results from bafilomycin A1 experiments 
indicate that TcdB enters the cytosol 40-50 min after toxin treatment (Figure 8). Taken 
together, these data indicate that irreversible CPE can be blocked within 20 minutes 
following cytosolic entry of TcdB.
One possible drawback of fusing LFn to fragments of TcdB is the possibility of 
disrupting folding of these fragments and thus attenuating otherwise normal enzymatic 
activity. The results that I have obtained using LFnTcdB fusion proteins corresponds 
very well with results of other groups who have microinjected similar fragments of TcdB. 
For example, Hoffinan et al. generated deletions of TcdB and found that an amino- 
terminal 546 amino acid fragment of TcdB contained enzymatic activity, while a 516 
amino acid fragment was 1000 fold less active [36]. This corresponds very well to the 
activity that I observed with the LFnTcdB^"^^  ^(active) and LFnTcdB^‘^ °® (inactive) fusion 
proteins. Additionally, the site-directed mutant W102A was first constructed and 
characterized by Busch et al. and found to posses a 1000 fold reduction in enzymatic 
activity compared to the wild type fragment [51], similar to the results I obtained by 
generating the same mutation in LFnTcdB '^^^ .^
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This work has contributed to the basic understanding of the structure of LCTs in general. 
Mutational analyses of LCTs, taken as a whole, provide insight into the structure of the 
enzymatic region of these toxins. Deletions as small as 35 amino acids from either the 
amino-terminal (Table 5) or carboxy-terminal ends [36] of the enzymatic domain render 
the protein inactive. This inactivation is due to a loss of hydrolase activity although 
neither of these regions has been shown to directly be involved in hydrolase activity, and 
neither shows homology with other known glucosyltransferases. Most likely, hydrolase 
activity is sensitive to small changes in conformation and these regions serve to stabilize 
the protein. The LFnTcdB '^^^^ fusion protein is reduced in glucosylhydrolase activity by 
approximately 12 fold and cytotoxicity by 100 fold compared to native TcdB. This is 
probably due to the addition of LFn (255 residues) to the amino-terminus of TcdB '^^^  ^
since other groups have reported enzymatic activity that paralleled that of the wild-type 
toxin from similar deletions of TcdB [36]. It is important, however, to use caution when 
making a direct comparison between the activities of LFnTcdB and the full-length 
toxin since they were purified by different methods and both proteins show reduced 
activity after storage.
Toxin A (TcdA) and Toxin B (TcdB) are the major virulence factors in the onset of 
Clostridium difficile associated disease (CDAD). Clostridium difficile is the most 
common etiologic agent of hospital-acquired diarrhea accounting for 10-25% of reported 
cases [54]. This organism is resistant to most commonly used broad range antibiotics 
including clindamycin, ampicillin, amoxicillin, and cephalosporins. Antibiotic treatment
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inhibits normal gut flora while allowing the colonization of resistant C. difficile in 
previously exposed patients. Since only two antibiotics, vancomycin and metronidazole 
are effective at treating CDAD, which can range from mild diarrhea to the more severe 
pseudomembranous colitis, antibiotic resistant strains of C. difficile are a real concern.
During the analysis of the enzymatic domain of TcdB, we found several mutants of this 
domain that were capable of ameliorating the CPE of this toxin. Due to the seriousness 
of CDAD, and the complications of treating this disease with antibiotics, these inhibitors 
provide a potential treatment. Since these inhibitory regions were fused to LFn, they 
could be easily delivered to patients in conjunction with PA. Experiments where these 
fusions were injected into mice indicate that effective delivery of these domains is 
occurring because mice die after injection with 100 finol of the enzymatic domain of 
TcdB.
In addition to providing a potential therapy for CDAD, these inhibitors also block the 
CPE of TcsL from C. sordellii (Figure 21), an organism isolated from gas gangrene 
infections [55, 56]. Clostridial gas gangrene infections are equally as serious as CDAD. 
Despite treatment with antibiotics, hyperbaric oxygen treatments, and surgery, 25% of 
cases still result in mortality [57]. The results reported herein, indicate that LFnTcdB^'^°° 
also inhibits the effects of TcsL on cells and could be used for the treatment of C. 
sordellii infections as well.
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While this work did not show conclusively that TcdA was inhibited by this mutant form 
of TcdB, TcdA shares substrates with TcdB and TcsL and LFnTcdB*'^*^” has been shown 
to inhibit CPE of both of these toxins. Additionally, L F n T c d B w a s  able to protect 
cells from the toxic effects of C. difficile supernatants that contain both TcdA and TcdB. 
Taken together, these results provide strong evidence for the inhibition of TcdA CPE by 
the LFnTcdB^'^”® fusion protein.
A major question still exists as to the mechanism of inhibition of LCTs by LFnTcdB*'^°°. 
The inhibition most likely occurs because of a competition for substrate or cosubstrate, 
although we could not rule out the possibility that LCTs form a higher order complex, 
and that these mutant forms somehow interfered with the assembly of this complex. Our 
results indicate that the competition is occurring inside of the cell since LFnTcdB is 
capable of inhibiting CPE of TcdB '^^^  ^ expressed inside transfected CHO cells. 
Additionally, the inhibition does not seem to be due to LFnTcdB sequestering UDP- 
glucose in the cell because a previously described site-directed mutant defective in UDP- 
glucose binding -demonstrating a Km that is 200 fold less than the wild type fragment 
[51]- was also able to inhibit CPE when generated as an LFn fusion and delivered to cells 
in conjunction with PA.
TcsL and TcdB have been shown to interact with amino acids 22-27 of their target 
GTPases. These amino acids are part of the p-loop and a l  helix both of which are known 
to interact with GEFs, GAPs, and/or downstream effector proteins [58]. If inhibition was 
occurring through protein interaction with substrate, then physiological effects on cells
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may be observed in the absence of enzymatic activity. For example, LFnTcdB*'^°° lacks 
enzymatic activity, but if it still interacts with substrate, it could prevent signaling to 
downstream effector proteins. A change in cell morphology was observed after extended 
treatment with the inhibitor suggesting there may be an interaction with substrate.
If inhibition was due to interaction of the inhibitor with substrate thus reducing the 
amount of substrate accessible to toxin, then inhibition should also be observed in vitro 
which was consistent with our results (Figure 24). In order to confirm substrate was 
protected from TcdB modification inside the cell in the presence of inhibitor, differential 
glucosylation assays were carried out on HeLa extracts prepared from cells during 
inhibition experiments. A target was identified, which was protected in cells treated with 
inhibitor and toxin, but not in cells treated with toxin alone (Figure 25). Interestingly, 
this target was much larger than Rho, Rac, or Cdc42. While one explanation seems to be 
that this target is a complex containing Rho, Rac, or Cdc42, it may be a target of LCTs 
that has not previously been identified. A likely candidate is one of the heteromeric G 
proteins, which contain some sequence similarity to small Rho GTPases.
Inhibition of TcsL CPE by the attenuated enzymatic domain of TcdB raises obvious 
questions. If TcsL targets different substrates than TcdB and inhibition is due to blocking 
substrate interaction, then why was TcsL inhibited by the substrate interacting region of 
TcdB? Since TcsL has recently been shown to modify the TcdB substrates Rho, Rac, and 
Cdc42 [12], it may be that inhibiting glucosylation of these substrates is sufficient to 
rescue cells from TcsL CPE. Alternatively, efficient targeting of Ras, Rap, and Ral may
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require at least two substrate recognition sites on the toxin. The second possibility is 
supported by results obtained from chimeric fusion proteins of TcdB and TcsL, where 
region 364-468 of TcdB and TcsL were sufficient for targeting Rho, Rac and Cdc42, but 
TcsL required this region and region 468-516 to efficiently target Ras, Rap, and Ral [12]. 
I propose that the truncated fusion proteins are able to bind to TcsL and TcdB target 
GTPases thus blocking interaction of the native toxins. I have generated a model, which 
fits the current understanding of TcdB and TcsL substrate interacting regions, to explain 
how this interaction may occur (Figure 31).
LFnTcdB fusion proteins provide insight into the location of the substrate recognition 
region of LCTs. The substrate recognition region of TcdB was previously narrowed to a 
region encompassing amino acids 364-468 [12]. Smaller regions have not been tested for 
the ability to interact with Rho, Rac, and Cdc42. Generation of a mutation at position 
365 previously believed to be part of the substrate recognition region, was sufficient to 
disrupt hydrolase activity, but did not impair substrate binding determined by this 
fragments ability to compete with wild type TcdB. These results indicate this region is 
probably not involved in substrate recognition. Furthermore, the effectiveness of the 1- 
420 amino acid fusion protein at inhibiting the activity of TcdB indicates that LFnTcdB^' 
contains an essential substrate recognition region. Taken together, these results 
indicate that the substrate recognition region of TcdB lies between amino acids 366-420.
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Figure 31. Model For Inhibition of LCTs by the Inhibitor LFnTcdB '^®**.
Rho, Rac, and Cdc42 have one substrate interacting region, and substrates 
interact with inhibitor reducing the interaction of TcdB with substrate. Ras 
Rap and Ral targeting requires two separate or overlapping substrate 
interacting regions, one which is shared with Rho, Rac, and Cdc42. The 
second is unique to Ras, Rap, and Ral. Interaction of LFnTcdB 1-500 with 
Ras Rap and Ral through the first shared recognition site is sufficient to 
inhibit the interaction of these substrates with TcsL.
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PA/LFn has proved vital for the cytosolic delivery of the truncated forms of TcdB 
described in this research. The LFnTcdB fusion proteins provide the first examples of 
truncated virulence factors that are able to inhibit the native virulence factor inside a 
mammalian cell. This inhibition activity has allowed us to narrow the substrate-binding 
region of TcdB. In addition, by entreating cells with PA/LFnTcdB*"^ ®® and TcdB we 
discovered a novel TcdB cellular target, which was protected from glucosylation in 
extracts from TcdB/inhibitor treated cells but not in extracts from TcdB treated cells. 
There are at least two lines of research that would be interesting to pursue in future work. 
Generating LFnTcdB fusion proteins with deletions in this substrate-binding region 
(amino acids 366-420) could further narrow the substrate recognition region of this toxin. 
Secondly, identification of this novel TcdB cellular target will provide insight into the 
cellular intoxication process for TcdB and LCTs in general.
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